<DOC>
	<DOCNO>NCT02036918</DOCNO>
	<brief_summary>This study aim evaluate patient metastatic castrate-resistant prostate cancer ( mCRPC ) undergo treatment sipuleucel-T evidence treatment-associated immune activation lymph node peripheral blood .</brief_summary>
	<brief_title>Dendreon Lymph Node Biopsy Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>This pilot study mCRPC patient plan undergo therapy sipuleucel-T immunotherapy . Consenting patient randomize 3:1 immediate sipuleucel-T immunotherapy follow lymph node biopsy ( post-treatment experimental group ) immediate lymph node biopsy follow sipuleucel-T immunotherapy ( pre-treatment control group ) . Peripheral blood collect , , treatment sipuleucel-T evaluated evidence sipuleucel-T induce immune activation . Lymph node collect biopsy also evaluate evidence sipuleucel-T induce immune activation . Patients follow 3 month safety 6 month disease progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . ECOG performance status 0 1 3 . Life expectancy ≥ 6 month 4 . Minimallysymptomatic asymptomatic , castrateresistant metastatic prostate cancer , evidence following : 1 . Histologicallyconfirmed diagnosis adenocarcinoma prostate 2 . Evidence adequate androgen deprivation , evidence one following : Bilateral orchiectomy Ongoing LHRH agonist ( e.g . leuprolide , goserelin ) serum testosterone &lt; 50 ng/dl Ongoing LHRH antagonist ( e.g . degarelix ) serum testosterone &lt; 50 ng/dl 3 . Evidence prostate cancer resistance castration , evidence one following : 2 consecutive PSA level ≥ 50 % PSA nadir achieve ADT obtain least 1 week apart CT MRI base evidence disease progression ( soft tissue nodal ) accord PCWG2 criterion RECIST 1.1 criterion , least 1 new bone scan lesion compare immediate prior radiologic study . 4 . Presence nonvisceral metastasis image 5 . Absence major symptom directly attributable prostate cancer , follow permissible exception : Ureteral obstruction secondary pelvic retroperitoneal lymphadenopathy Bladder outlet obstruction secondary locally recurrent prostate cancer 5 . Radiographic evidence lymphadenopathy , define lymph node great 1 cm diameter axial imaging ( CT MRI PET/CT ) 6 . Adequate laboratory parameter 7 . A minimum 4 week major surgery prior registration . Coincident standard care surgery research biopsy permit study . 1 . Prior treatment sipuleucelT 2 . Allergy component sipuleucelT 3 . Inability undergo leukapheresis 4 . History neuroendocrine variant prostate cancer , include small cell carcinoma prostate 5 . Extensive prior surgery/radiation present would render biopsy highly complex risk intraoperative injury high 6 . Any chronic medical condition require daily corticosteroid immunosuppressant 7 . Solid organ transplantation require immunosuppression 8 . Visceral ( e.g . lung , liver ) metastases 9 . Known brain metastasis 10 . History spinal cord compression 11 . Untreated/unstabilized pathologic long bone fracture 12 . Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability recurrence within 24 month 13 . Administration investigational therapeutic within 30 day registration 14 . Any condition , opinion investigator , would preclude participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>castrate resistant prostate cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>sipuleucel-T</keyword>
	<keyword>lymphadenectomy</keyword>
	<keyword>Excisional lymph node biopsy</keyword>
</DOC>